Coleman Mark 4
4 · Axsome Therapeutics, Inc. · Filed Sep 9, 2025
Insider Transaction Report
Form 4
Coleman Mark
Director
Transactions
- Purchase
Common Stock
2025-09-08$127.20/sh+800$101,760→ 47,437 total - Purchase
Common Stock
2025-09-08$127.30/sh+287$36,535→ 47,724 total - Purchase
Common Stock
2025-09-08$127.40/sh+488$62,171→ 48,212 total
Holdings
- 403,856(indirect: See Footnote)
Common Stock
Footnotes (2)
- [F1]Represents the open market purchase of shares of the Issuer's common stock.
- [F2]Such shares are held by an entity, of which the reporting person has voting and dispositive power, and therefore, the reporting person is deemed to be the indirect beneficial owner of such shares.